Revisiting policy on chronic HCV treatment under the Thai Universal Health Coverage: An economic evaluation and budget impact analysis

• Main Authors: Rattanavipapong W., Anothaisintawee T., Teerawattananon Y.
• Other Authors: SAW SWEE HOCK SCHOOL OF PUBLIC HEALTH
• Format: Article
• Published: Public Library of Science 2020
• Subjects: daclatasvir; ledipasvir; peginterferon alpha; ribavirin; sofosbuvir; antivirus agent; Article; budget; chronic hepatitis C; controlled study; cost benefit analysis; cost effectiveness analysis; cost utility analysis; drug cost; economic evaluation; health care cost; health care policy; health insurance; Hepatitis C virus genotype 3; Markov chain; quality adjusted life year; quality of life; tax; Thailand; combination drug therapy; cost; economic model; economics; female; genetics; genotype; genotyping technique; human; insurance; male; Antiviral Agents; Budgets; Costs and Cost Analysis; Drug Therapy, Combination; Female; Genotype; Genotyping Techniques; Hepatitis C, Chronic; Humans; Male; Models, Economic; Universal Coverage
• Online Access: https://scholarbank.nus.edu.sg/handle/10635/165968
• Institution: National University of Singapore

10.1371/journal.pone.0193112